Clinical Trial

Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma

Study acronym: TTV ccRCC
Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-04.
Trial Details
NCT Number NCT07018037
Lead Sponsor Regina Elena Cancer Institute
Conditions Renal Cell Carcinoma
Enrollment 20 participants
Start Date 2025-01-29
Primary Completion 2026-01-29 (estimated)
Study Completion 2027-01-29 (estimated)
Updated on ClinicalTrials.gov 2026-06-05